Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NR1H2 | P55055 | 1/20 | 0.35 |
| ▸ | ABCB1 | P08183 | 1/20 | 0.34 |
| ▸ | UCHL1 | P09936 | 1/20 | 0.33 |
| ▸ | PDE4B | Q07343 | 1/20 | 0.33 |
| ▸ | PARP1 | P09874 | 1/20 | 0.32 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.31 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.31 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.31 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.31 |
| ▸ | SRC | P12931 | 8/20 | 0.31 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.30 |
| ▸ | POLB | P06746 | 1/20 | 0.30 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.30 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.30 |
| ▸ | GPR119 | Q8TDV5 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24894673 | 1.00 | NR1H2 (0.35) | NR1H2ABCB1UCHL1PDE4BPARP1 | |
| SCHEMBL9383410 | 1.00 | NR1H2 (0.35) | NR1H2ABCB1UCHL1PDE4BPARP1 | |
| SCHEMBL3949196 | 1.00 | NR1H2 (0.35) | NR1H2ABCB1UCHL1PDE4BPARP1 | |
| SCHEMBL24826386 | 1.00 | NR1H2 (0.35) | NR1H2ABCB1UCHL1PDE4BPARP1 | |
| SCHEMBL12553792 | 1.00 | NR1H2 (0.35) | NR1H2ABCB1UCHL1PDE4BPARP1 | |
| SCHEMBL8759166 | 0.91 | NR1H2 (0.32) | NR1H2ABCB1PARP1 | |
| SCHEMBL8759141 | 0.91 | NR1H2 (0.32) | NR1H2ABCB1PARP1 | |
| SCHEMBL12519787 | 0.90 | NR1H2 (0.33) | NR1H2ABCB1UCHL1PARP1CHRM2 | |
| SCHEMBL1526484 | 0.90 | NR1H2 (0.35) | NR1H2ABCB1PARP1CHRM2CHRM1 | |
| SCHEMBL1526483 | 0.90 | NR1H2 (0.35) | NR1H2ABCB1PARP1CHRM2CHRM1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4359402-B1 | IMIDAZOLO INDAZOLE COMPOUNDS AS JAK INHIBITORS | THERAVANCE BIOPHARMA R&D IP LLC (US) | 2026-03-11 | — | — | EP | disclosed |
| US-12384761-B2 | Imidazolo indazole compounds as JAK inhibitors | THERAVANCE BIOPHARMA R&D IP, LLC (US) | 2025-08-12 | — | — | US | disclosed |
| EP-4359402-A1 | IMIDAZOLO INDAZOLE COMPOUNDS AS JAK INHIBITORS | Theravance Biopharma R&D IP, LLC (US) | 2024-05-01 | — | — | EP | disclosed |
| CN-117813298-A | Imidazole indazole compounds as JAK inhibitors | 施万生物制药研发IP有限责任公司 | 2024-04-02 | — | — | CN | disclosed |
| US-20240092758-A1 | IMIDAZOLO INDAZOLE COMPOUNDS AS JAK INHIBITORS | THERAVANCE BIOPHARMA R&D IP, LLC | 2024-03-21 | — | — | US | disclosed |
| WO-2022272020-A1 | IMIDAZOLO INDAZOLE COMPOUNDS AS JAK INHIBITORS | THERAVANCE BIOPHARMA R&D IP, LLC (US) | 2022-12-29 | — | — | WO | disclosed |
| CN-106632349-B | The hydrate and its preparation and application of the salt of pyran derivate or its salt | 海思科医药集团股份有限公司 | 2019-05-28 | — | — | CN | disclosed |
| CN-106632349-A | Pyran derivative salts or hydrates thereof, and preparation and applications of the salts and the hydrates | 四川海思科制药有限公司 | 2017-05-10 | — | — | CN | disclosed |
| CN-105531277-A | Pyrrolo-imidazole ring derivatives and their use in medicine | SICHUAN HAISCO PHARMACEUTICAL CO LTD | 2016-04-27 | — | — | CN | disclosed |
| CN-105037367-A | Amino six-membered ring derivative and application thereof in medicines | SICHUAN HAISCO PHARMACEUTICAL CO LTD | 2015-11-11 | — | — | CN | disclosed |
| US-8017611-B2 | Pyridine and pyrazine derivatives -083 | ASTRAZENECA AB (SE) | 2011-09-13 | — | — | US | disclosed |
| EP-2215085-B1 | PYRIDINE AND PYRAZINE DERIVATIVES USEFUL IN THE TREATMENT OF CELL PROLIFERATIVE DISORDERS | ASTRAZENECA AB (SE) | 2011-09-07 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240092758-A1 | IMIDAZOLO INDAZOLE COMPOUNDS AS JAK INHIBITORS | JAK1, JAK3, JAK2 | NR1H2 2644/4885ABCB1 1097/4885UCHL1 3729/4885 |
| US-12384761-B2 | Imidazolo indazole compounds as JAK inhibitors | JAK1, JAK3, JAK2 | NR1H2 2644/4885ABCB1 1097/4885UCHL1 3729/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.